CTNNB1 and hepatocellular carcinoma: Our work demonstrates that β-catenin is now targetable in murine HCC to overcome ICI resistance and supports the high impact development of clinical investigations utilizing LNP-CTNNB1 as a monotherapy or in combination with ICI to achieve therapeutic benefit in HCC patients with Wnt/β-catenin activation.